Rojo F - Search Results

1

DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.

Moncho-Amor V, Ibañez de Cáceres I, Bandres E, Martínez-Poveda B, Orgaz JL, Sánchez-Pérez I, Zazo S, Rovira A, Albanell J, Jiménez B, Rojo F, Belda-Iniesta C, García-Foncillas J, Perona R. Moncho-Amor V, et al. Among authors: rojo f. Oncogene. 2011 Feb 10;30(6):668-78. doi: 10.1038/onc.2010.449. Epub 2010 Oct 4. Oncogene. 2011. PMID: 20890299

2

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Molina MA, et al. Among authors: rojo f. Cancer Res. 2001 Jun 15;61(12):4744-9. Cancer Res. 2001. PMID: 11406546

3

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Albanell J, et al. Among authors: rojo f. Cancer Res. 2001 Sep 1;61(17):6500-10. Cancer Res. 2001. PMID: 11522647

4

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

Albanell J, Rojo F, Baselga J. Albanell J, et al. Among authors: rojo f. Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. doi: 10.1016/s0093-7754(01)90283-0. Semin Oncol. 2001. PMID: 11706397 Review.

5

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

Molina MA, Sáez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, García-Conde J, Baselga J, Clinton GM. Molina MA, et al. Among authors: rojo f. Clin Cancer Res. 2002 Feb;8(2):347-53. Clin Cancer Res. 2002. PMID: 11839648

6

TACE is required for the activation of the EGFR by TGF-alpha in tumors.

Borrell-Pagès M, Rojo F, Albanell J, Baselga J, Arribas J. Borrell-Pagès M, et al. Among authors: rojo f. EMBO J. 2003 Mar 3;22(5):1114-24. doi: 10.1093/emboj/cdg111. EMBO J. 2003. PMID: 12606576 Free PMC article.

7

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. Anido J, et al. Among authors: rojo f. Clin Cancer Res. 2003 Apr;9(4):1274-83. Clin Cancer Res. 2003. PMID: 12684395

8

mTOR signalling in human cancer.

Albanell J, Dalmases A, Rovira A, Rojo F. Albanell J, et al. Among authors: rojo f. Clin Transl Oncol. 2007 Aug;9(8):484-93. doi: 10.1007/s12094-007-0092-6. Clin Transl Oncol. 2007. PMID: 17720651 Review.

9

Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.

Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascón P, Rojo F, Perona R, Rovira A, Albanell J. Tapia MA, et al. Among authors: rojo f. Cell Cycle. 2007 Sep 15;6(18):2284-92. doi: 10.4161/cc.6.18.4721. Epub 2007 Jul 10. Cell Cycle. 2007. PMID: 17890907 Free article.

10

Pharmacodynamics: biological activity of targeted therapies in clinical trials.

Rojo F, Dalmases A, Corominas JM, Albanell J. Rojo F, et al. Clin Transl Oncol. 2007 Oct;9(10):634-44. doi: 10.1007/s12094-007-0116-2. Clin Transl Oncol. 2007. PMID: 17974524 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

477 results

Search Page